ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 436

Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study

Ali Guermazi1, Jeffrey Kraines2, Aida Aydemir2, Stephen Wax3, Michel Crema4, Marc C. Hochberg5 and Frank Roemer1,6, 1Radiology, Boston University School of Medicine, Boston, MA, 2EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 3EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, 4Boston University School of Medicine, Boston, MA, 5University of Maryland School of Medicine, Baltimore, MD, 6Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: cartilage, DMOAD, MRI, osteoarthritis and subchondral bone

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Osteoarthritis – Clinical Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sprifermin, a recombinant human fibroblast growth factor 18, is currently being investigated as a potential disease-modifying OA drug. Sprifermin treatment leads to a dose-dependent increase in femorotibial cartilage thickness, as well as medial and lateral compartment cartilage, over two years1. The aim of this post-hoc analysis was to evaluate the potential effects of sprifermin on additional knee structural endpoints, based on semi-quantitative MRI assessment over 24 months.

1Hochberg MC, et al. Arthritis Rheumatol. 2017; 69 (suppl 10).

Methods: Patients aged 40–85 years with symptomatic radiographic primary femorotibial OA according to ACR criteria, Kellgren-Lawrence Grade  2 or 3, and medial minimum joint space width ≥2.5 mm in the target knee were randomized (1:1:1:1:1) to receive double-blinded sprifermin (30 μg or 100 μg) or placebo, administered as three weekly intra-articular injections in 6- or 12-month cycles. 1.5 or 3 Tesla MRIs were acquired at baseline, 6, 12, 18 and 24-month follow-up visits using a standard protocol (NCT01033994).

MRIs were read using the Whole-Organ Magnetic Resonance Imaging Score (WORMS) system by three trained musculoskeletal radiologists at baseline, 12 and 24 months. Analyses of all sprifermin and placebo arms included multiple MRI-defined OA features and multi-dimensional assessments: (a) delta-subregional approach (the difference in the number of subregions with worsening as compared to improvement) and (b) delta-sum approach (absolute scores of all subregions). Analyses were performed on a whole knee level and separately for medial, lateral, and patellofemoral compartments. To test for potential dose-response effects, the Jonckheere-Terpstra (asymptotic) test was used. P-values were not adjusted for multiple testing.

 

Results: In total, 549 patients were included. A dose-dependent treatment effect for sprifermin on cartilage morphology (i.e., less worsening of cartilage damage) was observed for the entire knee from baseline to 24 months using both delta sum and delta subregion approaches (Table 1). For bone marrow lesions (BMLs), a dose-dependent treatment effect (improvement of BMLs) was observed from baseline to 24 months for the patello-femoral joint, using both delta sum and delta subregion approaches, but not in the other compartments (Table 2). No significant changes from baseline to 24-months were reported in Hoffa-synovitis, effusion-synovitis, menisci, or osteophytes.

 

Conclusion: Sprifermin has a positive effect on cartilage morphology based on semi-quantitative assessment, in addition to the previously reported effect on cartilage thickness based on 3D morphometry. Sprifermin was also associated with BML improvement in the patello-femoral joint. There were no significant effects associated with sprifermin on the other joint tissues assessed, and no additional safety concerns. 


Disclosure: A. Guermazi, MerckSerono, 5,Genzyme, 5,AstraZeneca, 5,TissueGene, 5,OrthoTrophix, 5,Boston Imaging Core Lab (BICL), LLC, 9; J. Kraines, EMD Serono, 3; A. Aydemir, EMD Serono, 3; S. Wax, EMD Serono, 3; M. Crema, Boston Imaging Core Lab BICL), LLC., 1; M. C. Hochberg, Bioberica, 5,EMD Serono, 5,Novartis Pharma AG, 5,Plexxikon, 5,Pfizer, Inc., 5,Proximagen, 5,Regeneron, 5,Samumed, LLC, 5,Theralogix LLC, 5; F. Roemer, BICL, 4.

To cite this abstract in AMA style:

Guermazi A, Kraines J, Aydemir A, Wax S, Crema M, Hochberg MC, Roemer F. Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/structural-effects-of-intra-articular-sprifermin-in-symptomatic-radiographic-knee-osteoarthritis-a-post-hoc-analysis-of-cartilage-morphology-over-the-2-year-treatment-period-of-a-5-year-randomized-p/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/structural-effects-of-intra-articular-sprifermin-in-symptomatic-radiographic-knee-osteoarthritis-a-post-hoc-analysis-of-cartilage-morphology-over-the-2-year-treatment-period-of-a-5-year-randomized-p/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology